DS-2243

N/A

Report date: 2026/03/19 17:12:28

Base Information

Drug NameDS-2243

Drug Alias NameDS-2243aDS-2243

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-HLA-A2Anti-NY-ESO-1CD3 T-cell engagers

TargetsHLA Class I Histocompatibility Antigen, A-2 alpha ChainCancer/testis antigen 1T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumoursSarcoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesNetherlands +[5]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDaiichi Sankyo Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursSarcoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A